BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Lawyer files suit to shut Ranbaxy plants in India

June 10, 2013 | News | By BioSpectrum Bureau



New Delhi: An Indian lawyer has filed a lawsuit asking the country's Supreme Court to probe the pharmaceutical giant, its executives and even the Indian regulators.

The country's generic giant, Ranbaxy Laboratories had in May this year made a $500 million settlement to the US FDA after accepting to have sold adulterated drugs in the US market.

Also read:

- Ranbaxy controversy: What have been the highlights?
- Ranbaxy's fall from grace

Ã?Â

The public interest litigation (PIL) urged the Supreme Court to shut down the two manufacturing plants identified by the US FDA and further wants the court to order the country's Central Bureau of Investigation (CBI) to investigate the US case. The suit further claimed that corruption within the organisation prevailed because of lax Indian regulation and hence it seeks a probe of regulators who oversaw the company.

The lawyer, Mr Manoharlal Sharma, pointed out in his lawsuit that Ranbaxy drugs that have been banned by the US are still being sold in the Indian market. "It is not a tale of cutting corners or lax manufacturing practices, but one of outright fraud, in which the company knowingly sold substandard drugs around the world, including in India, Africa and the US while working to deceive regulators," the PIL said.

Drug Controller General of India (DCGI), Dr G N Singh, said that his department is probing the issue. Ranbaxy meanwhile released a public statement assuring that all their products in both the Indian and globla markets are safe and effective.

Ã?Â

Ã?Â